The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States despite most cases being preventable by vaccination. HPV vaccine efficacy varies in relationship to when the vaccine is administered, with greater efficacy obtained if administered prior to sexual debut. Historically, this vaccine was created to protect women from cervical cancer. As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders. HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts. This article aims to explain the benefits of HPV immunization for the gender the farthest from meeting vaccination goals, boys, and young men. This article expounds on the school nurses’ role in promoting vaccination to prevent HPV infection and the sequela of related cancers.
AlemanyL.SaunierM.Alvarado-CabreroI.QuirosB.SalmeronJ.ShinH. R.PirogE. C.GuimeraN.Hernandez-SuarezG.FelixA.ClaveroO.LloverasB.KasamatsuE.GoodmanM. T.HernandezB. Y.LacoJ.TinocoL.GeraetsD. T.LynchC. F., . . . HPV VVAP Study Group. (2015). Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. International Journal of Cancer, 136(1), 98-107. https://doi.org/10.1002/ijc.28963
AthanasiouA.BowdenS.ParaskevaidiM.FotopoulouC.Martin-HirschP.ParaskevaidisE.KyrgiouM. (2020). HPV vaccination and cancer prevention. Best Practice & Research Clinical Obstetrics & Gynaecology, 65, 109-124. https://doi.org/10.1016/j.bpobgyn.2020.02.009
4.
CaloW. A.LennonR. P.Ruffin IvM. T.KellerC.SpanosK.D’SouzaG.KraschnewskiJ. L. (2022). Support for HPV vaccine school-entry requirements in the United States: The role of exemption policies. Vaccine, 40(51), 7426-7432. https://doi.org/10.1016/j.vaccine.2022.08.019
5.
Centers for Disease Control and Prevention. (2022). Cancers associated with human papillomavirus, United States—2015–2019 (USCS Data Brief, no. 32). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. https://www.cdc.gov/cancer/hpv/statistics/cases.htm
6.
ChaturvediA. K.GraubardB. I.BroutianT.PickardR. K. L.TongZ. Y.XiaoW.KahleL.GillisonM. L. (2018). Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. Journal of Clinical Oncology, 36(3), 262-267. https://doi.org/10.1200/JCO.2017.75.0141
7.
ChessonH. W.DunneE. F.HaririS.MarkowitzL. E. (2014). The estimated lifetime probability of acquiring human papillomavirus in the United States. Sexually Transmitted Diseases, 41(11), 660-664. https://doi.org/10.1097/OLQ.0000000000000193
8.
da Costa NunesJ. F.PiresS.ChadeD. C. (2020). Human papillomavirus vaccination and prevention of intraepithelial neoplasia and penile cancer: Review article. Current Opinion in Urology, 30(2), 208-212. https://doi.org/10.1097/MOU.0000000000000730
9.
da RochaW. M.da SilvaK. C.CavalcantiS. M. B. (2019). The role of oncogenic DNA viruses in penile cancer development. Critical Reviews in Oncogenesis, 24(4), 385-402. https://doi.org/10.1615/CritRevOncog.2020032961
10.
de MartelC.GeorgesD.BrayF.FerlayJ.CliffordG. M. (2020). Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. The Lancet Global Health, 8(2), e180-e190. https://doi.org/10.1016/s2214-109x(19)30488-7
11.
DeshmukhA. A.SukR.ShielsM. S.SonawaneK.NyitrayA. G.LiuY.GaisaM. M.PalefskyJ. M.SigelK. (2020). Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015. Journal of the National Cancer Institute, 112(8), 829-838. https://doi.org/10.1093/jnci/djz219
12.
Food and Drug Administration. (2018). Prescribing information [package insert]. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant). U.S. Department of Health and Human Services, Food and Drug Administration. https://www.fda.gov/media/90064/download
GiulianoA. R.PalefskyJ. M.GoldstoneS.MoreiraE. D.Jr.PennyM. E.ArandaC.VardasE.MoiH.JessenH.HillmanR.ChangY. H.FerrisD.RouleauD.BryanJ.MarshallJ. B.VuocoloS.BarrE.RadleyD.HauptR. M.GurisD. (2011). Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. New England Journal of Medicine, 364(5),401-411. https://doi.org/10.1056/NEJMoa0909537
15.
GoldstoneS. E.GiulianoA. R.PalefskyJ. M.Lazcano-PonceE.PennyM. E.CabelloR. E.MoreiraE. D.BaraldiE.JessenH.FerenczyA.KurmanR.RonnettB. M.StolerM. H.BautistaO.DasR.GroupT.LuxembourgA.ZhouH. J.SaahA. (2022). Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: Results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 22(3), 413-425. https://doi.org/10.1016/s1473-3099(21)00327-3
16.
HerreroR.QuintW.HildesheimA.GonzalezP.StruijkL.KatkiH. A.PorrasC.SchiffmanM.RodriguezA. C.SolomonD.JimenezS.SchillerJ. T.LowyD. R.van DoornL.-J.WacholderS.KreimerA. R. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLOS ONE, 8, Article e68329. https://doi.org/10.1371/journal.pone.0068329
17.
JouraE. A.PilsS. (2016). Vaccines against human papillomavirus infections: Protection against cancer, genital warts or both?Clinical Microbiology and Infection, 22(Suppl. 5), S125-S127. https://doi.org/10.1016/j.cmi.2016.12.017
18.
KaulS.DoT. Q. N.HsuE.SchmelerK. M.MontealegreJ. R.RodriguezA. M. (2019). School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas. Papillomavirus Research, 8, Article 100189. https://doi.org/10.1016/j.pvr.2019.100189
19.
KreimerA. R.ShielsM. S.FakhryC.JohanssonM.PawlitaM.BrennanP.HildesheimA.WaterboerT. (2018). Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. Cancer, 124(9), 1859-1866. https://doi.org/10.1002/cncr.31256
20.
LapriseC.MadathilS. A.SchlechtN. F.CastonguayG.SoulieresD.Nguyen-TanP. F.AllisonP.CoutleeF.HierM.RousseauM. C.FrancoE. L.NicolauB. (2017). Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. Oral Oncology, 69, 56-61. https://doi.org/10.1016/j.oraloncology.2017.03.013
21.
LiaoC. I.FrancoeurA. A.KappD. S.CaesarM. A. P.HuhW. K.ChanJ. K. (2022). Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Network Open, 5(3), Article e222530. https://doi.org/10.1001/jamanetworkopen.2022.2530
22.
McGovernJ.FullerC.BurrisK. (2021). Anal cancer screening and prevention: A review for dermatologists. Journal of the European Academy of Dermatology and Venereology, 35(8), 1622-1627. https://doi.org/10.1111/jdv.17263
23.
Meeting of the Global Advisory Committee on Vaccine Safety. (2017, July14). Geneva, Switzerland.
24.
MeitesE.SzilagyiP. G.ChessonH. W.UngerE. R.RomeroJ. R.MarkowitzL. E. (2019). Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 68(32), 698-702. https://doi.org/10.15585/mmwr.mm6832a3
25.
MillerK.DilleyS. E.HuhW. K. (2018). Lessons learned from domestic and international human papillomavirus vaccination programs: A review. American Journal of Obstetrics and Gynecology, 218(5), 467-473. https://doi.org/10.1016/j.ajog.2017.08.109
National Association of School Nurses. (2016). Framework for 21st century school nursing practice: National Association of School Nurses. NASN School Nurse, 31(1), 45-53. https://doi.org/10.1177/1942602X15618644
28.
NdiayeC.MenaM.AlemanyL.ArbynM.CastellsaguéX.LaporteL.BoschF. X.de SanjoséS.TrottierH. (2014). HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. The Lancet Oncology, 15(12), 1319-1331. https://doi.org/10.1016/s1470-2045(14)70471-1
29.
OlesenT. B.SandF. L.RasmussenC. L.AlbieriV.ToftB. G.NorrildB.MunkC.KjærS. K. (2019). Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: A systematic review and meta-analysis. The Lancet Oncology, 20(1), 145-158. https://doi.org/10.1016/s1470-2045(18)30682-x
30.
Osazuwa-PetersN.Adjei BoakyeE.MohammedK. A.ToboB. B.GeneusC. J.SchootmanM. (2017). Not just a woman’s business! Understanding men and women’s knowledge of HPV, the HPV vaccine, and HPV-associated cancers. Preventive Medicine, 99, 299-304. https://doi.org/10.1016/j.ypmed.2017.03.014
31.
PalefskyJ. M.GiulianoA. R.GoldstoneS.MoreiraE. D.Jr.ArandaC.JessenH.HillmanR.FerrisD.CoutleeF.StolerM. H.MarshallJ. B.RadleyD.VuocoloS.HauptR. M.GurisD.GarnerE. I. (2011). HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine, 365, 1576-1585. https://doi.org/10.1056/NEJMoa1010971
32.
PetajaT.KeranenH.KarppaT.KawaA.LantelaS.Siitari-MattilaM.LevanenH.TocklinT.GodeauxO.LehtinenM.DubinG. (2009). Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. Journal of Adolescent Health, 44(1), 33-40. https://doi.org/10.1016/j.jadohealth.2008.10.002
33.
PhillipsA.PatelC.PillsburyA.BrothertonJ.MacartneyK. (2018). Safety of human papillomavirus vaccines: An updated review. Drug Safety, 41(4), 329-346. https://doi.org/10.1007/s40264-017-0625-z
34.
Pierce CampbellC. M.KreimerA. R.LinH.-Y.FulpW.O’KeefeM. T.InglesD. J.AbrahamsenM.VillaL. L.Lazcano-PonceE.GiulianoA. R. (2015). Long-term persistence of oral human papillomavirus type 16: The HPV infection in men (HIM) study. Cancer Prevention Research, 8(3), 190-196. https://doi.org/10.1158/1940-6207.Capr-14-0296
35.
PingaliC.YankeyD.Elam-EvansL.MarkowitzL.WilliamsC.FreduaB.McNamaraL. A.StokleyS.SingletonJ. A.SingletonJ. A. (2021). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2020. Morbidity and Mortality Weekly Report, 75, 1183-1190. https://doi.org/10.15585/mmwr.mm7035a1
36.
RaneM. S.PageL. C.McVeighE.MillerK.BaureD.Elizabeth HalloranM.DuchinJ. S. (2021). Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. Vaccine, 39(12), 1765-1772. https://doi.org/10.1016/j.vaccine.2021.02.006
37.
SatterwhiteC. L.TorroneE. E.MeitesE. F.DunneE. F.MahajanR.OcfemiaM. C. B.SuJ.XuF.WeinstockH. (2013). Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sexually Transmitted Diseases, 40(3), 187-193. https://doi.org/10.1097/OLQ.0b013e318286bb53
38.
SenkomagoV.HenleyS. J.ThomasC. C.MixJ. M.MarkowitzL. E.SaraiyaM. (2019). Human papillomavirus-attributable cancers—United States, 2012-2016. Morbidity and Mortality Weekly Report, 68(33),724-728. https://doi.org/10.15585/mmwr.mm6833a3
39.
ShimabukuroT. T.SuJ. R.MarquezP. L.Mba-JonasA.AranaJ. E.CanoM. V. (2019). Safety of the 9-valent human papillomavirus vaccine. Pediatrics, 144(6), Article e20191791. https://doi.org/10.1542/peds.2019-1791
40.
SonawaneK.SukR.ChiaoE. Y.ChhatwalJ.QiuP.WilkinT.NyitrayA. G.SikoraA. G.DeshmukhA. A. (2017). Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Annals of Internal Medicine, 167(10), 714-724. https://doi.org/10.7326/M17-1363
VanderpoolR. C.BrehenyP. J.TillerP. A.HuckelbyC. A.EdwardsA. D.UpchurchK. D.PhillipsC. A.WeymanC. F. (2015). Implementation and evaluation of a school-based human papillomavirus vaccination program in Rural Kentucky. American Journal of Preventive Medicine, 49(2), 317-323. https://doi.org/10.1016/j.amepre.2015.05.001
43.
WallingE. B.BenzoniN.DornfeldJ.BhandariR.SiskB. A.GarbuttJ.ColditzG. (2016). Interventions to improve HPV vaccine uptake: A systematic review. Pediatrics, 138(1), Article e20153863. https://doi.org/10.1542/peds.2015-3863
44.
WorkowskiK. A.BolanG. A. (2015). Sexually transmitted diseases treatment guidelines, 2015 [Recommendations and reports]. Morbidity and Mortality Weekly Report, 64, 1-137.
45.
YanofskyV.PatelR.GoldenbergG. (2012). Genital warts: A comprehensive review. Journal of Clinical and Aesthetic Dermatology, 5(6), 25-36.
